Clinical trials
HER2 + Breast Cancer clinical trials
Below are recruiting her2 + breast cancer clinical trials, each written for real people, not researchers. We’re tracking 952 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07137416RecruitingPhase 1
Combination drug study for HER2-positive breast and other cancers
This study tests a new combination of two anti-cancer drugs (CX-5461 and T-DXd) for people with HER2-positive breast cancer or other solid tumors. It aims to see if the combination is safe and how well it works.
Boston, MassachusettsAges 18 years+ - NCT05296577RecruitingPhase 2
Combination treatment for advanced breast cancer
This trial tests a combination of two drugs, anlotinib and vinorelbine, for people with advanced breast cancer that is HER2-negative. It aims to see if this combination can help when other treatments have stopped working.
Zhengzhou, HenanAges 18 years+ - NCT07683754RecruitingPhase 3
T-DXd with hormone therapy for HER2-positive breast cancer
This trial tests a targeted drug combination for HER2-positive, hormone-receptor-positive breast cancer that has spread. It aims to shrink tumors and control the disease for as long as possible, with a planned switch to maintenance therapy after initial response.
Columbia, MarylandAges 18 years+ - NCT07619534Recruiting
Collecting Spinal Fluid from Advanced Breast Cancer Patients
This study collects spinal fluid samples from people with advanced (metastatic) HER2-positive or triple-negative breast cancer who have never had, and currently do not have, cancer spread to the brain. Researchers want to understand how cancer cells might reach the nervous system and develop better treatments.
Bethesda, MarylandAges 18–120 - NCT06663748RecruitingPhase 2
ARX788 for HER2-positive metastatic breast cancer
This trial studies a new drug called ARX788 for people with HER2-positive breast cancer that has spread or cannot be removed. It aims to see if the drug can shrink tumors and help patients live longer.
Zhengzhou, HenanAges 18–75 - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Little Rock, ArkansasAges 19 years+ - NCT04305834RecruitingPhase 2
Abemaciclib plus hormone pills for metastatic breast cancer in older adults
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
Duarte, CaliforniaAges 70 years+ - NCT06774027Recruiting
Breast cancer antibody-drug conjugate treatment registry
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
San Francisco, CaliforniaAges 18 years+ - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Jonesboro, ArkansasAges 18 years+ - NCT07726342RecruitingPhase 2
Study of a new drug for advanced HER2-positive breast cancer
This study tests a new drug, SMP-656, for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if it can help shrink or control the cancer.
Hefei, AnhuiAges 18 years+ - NCT07203729RecruitingPhase 2
A new drug for advanced breast cancer with severe symptoms
This trial tests a new drug called SHR-A1811 (a type of targeted therapy) for people with advanced breast cancer that is HER2-low and is causing severe symptoms (visceral crisis). The drug is given alone and aims to control the cancer and relieve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Beverly Hills, CaliforniaAges 18 years+ - NCT04281641Recruiting
Testing marker-guided treatment before surgery for HER2-positive breast cancer
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04481932RecruitingPhase 2
Trastuzumab with chemo for HER2-positive breast cancer
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT03591276RecruitingPhase 1/Phase 2
Doxorubicin plus pembrolizumab for hormone-resistant breast cancer
This Phase 1b/2 trial tests a combination of pegylated liposomal doxorubicin and pembrolizumab for breast cancer that no longer responds to hormone treatment. It aims to see how well the combination works and how safely it can be given to patients with advanced disease.
JerusalemAges 18 years+ - NCT04750122RecruitingPhase 1/Phase 2
Drug-screening guided treatment before surgery for HER2 breast cancer
This trial tests a treatment plan that is chosen using drug-testing in a lab (to see which medicines may work best) before surgery. It is for people with early-stage HER2-positive breast cancer, aiming to improve outcomes by guiding the right treatment early.
Beijing, Beijing MunicipalityAges 18–75 - NCT04576143RecruitingPhase 2/Phase 3
Dose-dense chemo before surgery for HER2-negative breast cancer
This trial studies a faster, higher-frequency chemotherapy schedule given before surgery for HER2-negative breast cancer. It aims to see if this approach works better and is safe for the patient’s cancer stage.
Hangzhou, ZhejiangAges 18–70 - NCT04136782RecruitingPhase 4
Tests two chemo drug combinations for triple-negative breast cancer
This Phase 4 trial compares two chemotherapy combinations to treat stage II–III triple-negative breast cancer. It looks for which regimen works better and is tolerated in people with measurable tumors and good overall health.
Harbin, HeilongjiangAges 18–70 - NCT04993014RecruitingPhase 2
De-escalating treatment after HER2-positive breast cancer responds
This study looks at whether some people with HER2-positive breast cancer can safely receive less (de-escalated) treatment after they finish chemotherapy plus HER2-targeted drugs before surgery. It specifically focuses on people whose cancer shows a complete response on the surgery pathology report.
São PauloAges 18 years+ - NCT05059379RecruitingPhase 3
Different radiation fields after breast cancer surgery
This trial compares two ways of giving radiation to lymph node areas near the collarbone after surgery for invasive breast cancer. It aims to see which radiation approach works better and is safer for preventing cancer returning in these lymph nodes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02535221RecruitingPhase 3
Hormone treatment vs chemotherapy before breast surgery
This Phase 3 trial compares hormone-based treatment versus chemotherapy given before surgery in people who are premenopausal and have hormone-receptor positive, HER2-negative breast cancer. It looks to see which approach works better to control the cancer before the breast operation.
BeijingAges 35–55 - NCT05292742RecruitingPhase 2
Continue targeted breast cancer therapy or switch to a new combo
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
Fuzhou, FujianAges 18–75 - NCT04836156RecruitingPhase 1/Phase 2
Personalized pre-surgery treatment for HER2-negative early breast cancer
This study tests a treatment plan chosen using lab drug testing on a patient’s tumor (in a dish). It may help improve outcomes for people with early breast cancer that is HER2-negative by matching therapy to what the tumor seems sensitive to.
BeijingAges 18–75 - NCT05314114Recruiting
Skipping underarm surgery for some breast cancers after chemotherapy
This trial studies whether it’s safe to skip removing underarm lymph nodes (axillary surgery) for people with certain breast cancers after they respond to “NACT,” a type of chemotherapy. It also uses planned breast-conserving surgery and whole-breast radiation to see if outcomes stay similar while reducing surgery-related side effects.
Beijing, Beijing MunicipalityAges 18–70
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
HER2 + Breast Cancer trials by city
Studies with a site in or near these metro areas.
HER2 + Breast Cancer trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for her2 + breast cancer?
- Yes. Clin2 currently lists 952 recruiting her2 + breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 + breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 + breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.